646502-89-8Relevant articles and documents
DEUTERATED SGC STIMULATORS
-
, (2021/10/02)
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine onophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: or a pharmaceutically acceptable salt thereof, wherein each of Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8 and Y9 is independently selected from hydrogen and deuterium, as well as pharmaceutical compositions, methods and uses thereof.
HYDROGEN ISOTOPE-ENRICHED ANALOGUES OF 1,2,4-OXANDIAZOLE BENZOIC ACID COMPOUNDS, COMPOSITIONS AND USES THEREOF
-
Paragraph 00157, (2017/07/14)
Novel hydrogen isotope-enriched 1,2,4-oxadiazole benzoic acid compounds, methods of their use and pharmaceutical compositions thereof are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature tra